{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:46:29Z","timestamp":1761630389867},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T00:00:00Z","timestamp":1130976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s10067-005-0071-7","type":"journal-article","created":{"date-parts":[[2005,11,2]],"date-time":"2005-11-02T08:36:43Z","timestamp":1130920603000},"page":"769-771","source":"Crossref","is-referenced-by-count":21,"title":["Infliximab in a child with therapy-resistant systemic vasculitis"],"prefix":"10.1007","volume":"25","author":[{"given":"Sandra W. K.","family":"de Kort","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion A. J.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,11,3]]},"reference":[{"key":"71_CR1","unstructured":"Petty RE, Cassidy JT (2000) Vasculitis and its classification. In: Cassidy JT and Petty RE (eds) Textbook of Pediatric Rheumatology. WB Saunders Company, pp 564\u2013603"},{"key":"71_CR2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0022-3476(05)80428-7","volume":"2","author":"S Ozen","year":"1992","unstructured":"Ozen S, Besbas N, Saatci U, Bakkaloglu A (1992) Diagnostic criteria for polyarteritis nodosa in childhood. J Pediatr 2:206\u2013209","journal-title":"J Pediatr"},{"key":"71_CR3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1521-6942(02)90237-8","volume":"16","author":"S Ozen","year":"2002","unstructured":"Ozen S (2002) The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol 16:411\u2013425","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"71_CR4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jpeds.2004.06.046","volume":"145","author":"S Ozen","year":"2004","unstructured":"Ozen S, Anton J, Arisoy N, Bakkaloglu A, Besbas N, Brogan P, et al. (2004) Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr 145:517\u2013522","journal-title":"J Pediatr"},{"key":"71_CR5","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","volume":"41","author":"P Bartolucci","year":"2002","unstructured":"Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L (2002) Efficacy of the anti-TNF-\u03b1 antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 41:1126\u20131132","journal-title":"Rheumatology"},{"key":"71_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/cyto.1995.1003","volume":"7","author":"SA Siegel","year":"1995","unstructured":"Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe S, Probert L, et al. (1995) The mouse\/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and lethality in vivo. Cytokine 7:15\u201325","journal-title":"Cytokine"},{"key":"71_CR7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1136\/adc.85.6.478","volume":"85","author":"HM Coutinho","year":"2001","unstructured":"Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS (2001) De novo malignancy after paediatric renal replacement therapy. Arch Dis Child 85:478\u2013483","journal-title":"Arch Dis Child"},{"key":"71_CR8","first-page":"2571","volume":"29","author":"L Huong du","year":"2002","unstructured":"Huong du L, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29:2571\u20132576","journal-title":"J Rheumatol"},{"key":"71_CR9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, Van Der Heijde DMFM, William St. Clair E, Furst DE, Breedveld FC, Kalden JR, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594\u20131602","journal-title":"N Engl J Med"},{"key":"71_CR10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"P Rutgeerts","year":"1999","unstructured":"Rutgeerts P, D\u2019Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2032s disease. Gastroenterology 117:761\u2013769","journal-title":"Gastroenterology"},{"key":"71_CR11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","volume":"15","author":"A Booth","year":"2004","unstructured":"Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. (2004) Prospective study of TNF\u03b1 blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 15:717\u2013721","journal-title":"J Am Soc Nephrol"},{"key":"71_CR12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.11204","volume":"49","author":"FT Saulsbury","year":"2003","unstructured":"Saulsbury FT, Mann JA (2003) Treatment with infliximab for a child with Beh\u00e7et\u2019s disease. Arthritis Rheum 49:599\u2013600","journal-title":"Arthritis Rheum"},{"key":"71_CR13","first-page":"808","volume":"31","author":"JE Weiss","year":"2004","unstructured":"Weiss JE, Eberhard BA, Chowdhury D, Gottlieb B (2004) Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 31:808\u2013810","journal-title":"J Rheumatol"},{"key":"71_CR14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.62.3.245","volume":"62","author":"P Lahdenne","year":"2003","unstructured":"Lahdenne P, V\u00e4h\u00e4salo, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62:245\u2013247","journal-title":"Ann Rheum Dis"},{"key":"71_CR15","first-page":"s152","volume":"20","author":"C Antoni","year":"2002","unstructured":"Antoni C, Braun J (2002) Side effects of anti-TNF therapy: Current knowledge. Clin Exp Rheumatol 20:s152\u2013s157","journal-title":"Clin Exp Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-005-0071-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-005-0071-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-005-0071-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:50:51Z","timestamp":1559119851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-005-0071-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,3]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["71"],"URL":"https:\/\/doi.org\/10.1007\/s10067-005-0071-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,3]]}}}